Thus, chemotherapy and immunotherapy may rapidly induce pyroptosis and boost antitumor immunity by increasing the recruitment and activation of CD8+ and NK cells in glioma, which could explain why the pyroptosis subtype C1 and high GPIs were associated with higher TMZ sensitivity and better anti-PD1 therapy response. The gene discussed is PDCD1; the disease is central nervous system cancer.